Proof-of-concept trial of intranasal epinephrine (G2B011)
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2014
Price : $35 *
At a glance
- Drugs Epinephrine (Primary)
- Indications Anaphylaxis
- Focus Pharmacokinetics; Proof of concept
- Sponsors G2B Pharma; Shin Nippon Biomedical Laboratories
- 13 Oct 2014 New trial record
- 13 Aug 2014 Results published in G2B Pharma media release.
- 13 Aug 2014 This proof-of-concept trial was successfully completed in 2013, according to a G2B Pharma media release.